Clinically important interaction between tedisamil and verapamil.

摘要: Tedisamil, a class III antiarrhythmic drug, is P-glycoprotein substrate. Tedisamil treatment may implicate coadministration with IV antiarrhythmics such as verapamil, inhibitor. Pharmacokinetic and pharmacodynamic interactions between tedisamil verapamil were evaluated in double-blind, crossover study. Twelve healthy volunteers received 3-day of (100 mg bid), (180 combination these drugs, or placebo. Blood pressure electrocardiograms assessed daily cardiac output pharmacokinetics on day 3. Combination increased plasma concentrations (AUC(0-12 h): +77%, CI(90%): +51% to +108%; C(max): +78%, +57% +102%) compared monotreatment but decreased -21%, -32% -8%; -28%, -39% -14%) norverapamil -17%, -28% -6%; -20%, CI(90%):-29% -10%) monotreatment. Compared placebo, the PR by 23.5 (CI(95%): 17.9 29.2) ms 12.2 (5.7 17.0) ms, respectively. QTc 27.8 (15.8 39.8) 45.7 (33.7 57.7) Thus, concomitant use inhibitors likely results clinically significant drug interactions.